WithdrawnPhase 2NCT00003273
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Studying Neuroblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NYU Langone Health
- Principal Investigator
- Jonathan L. Finlay, MB, ChBNYU Langone Health
- Intervention
- filgrastim(biological)
- Eligibility
- 10 years · All sexes
- Timeline
- 1997
Study locations (19)
- Cancer Research Center of Hawaii, Honolulu, Hawaii, United States
- Maine Children's Cancer Program, Scarborough, Maine, United States
- Spectrum Health and DeVos Children's Hospital, Grand Rapids, Michigan, United States
- Children's Hospital of Omaha, Omaha, Nebraska, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Winthrop University Hospital, Mineola, New York, United States
- NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- Herbert Irving Comprehensive Cancer Center, New York, New York, United States
- Beth Israel Hospital North, New York, New York, United States
- State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States
- State University of New York - Upstate Medical University, Syracuse, New York, United States
- Albert Einstein Clinical Cancer Center, The Bronx, New York, United States
- St. Vincent Mercy Medical Center, Toledo, Ohio, United States
- Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003273 on ClinicalTrials.govOther trials for Neuroblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07549321A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma PatientsRenaissance Pharma Ltd.
- RECRUITINGPHASE1, PHASE2NCT06625190Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsUniversity of Florida
- RECRUITINGPHASE1NCT07172958Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)Children's National Research Institute
- RECRUITINGPHASE2NCT07085338A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory NeuroblastomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT07399821An Imaging Study of Anti-GD2-800CW in Patients With NeuroblastomaPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPHASE1NCT06995872Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory NeuroblastomaNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT06814496Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsUniversity of Arizona
- RECRUITINGPHASE1NCT07087002GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young AdultsStanford University